Last reviewed 2026-04-23 · How we verify

MSI-78

MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens.

MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens. Used for Diabetic foot ulcers with Pseudomonas aeruginosa infection, Multidrug-resistant gram-negative bacterial infections.

At a glance

Mechanism of action

MSI-78 is a synthetic antimicrobial peptide derived from magainin that works by inserting into and destabilizing bacterial cell membranes, leading to cell lysis and death. It is designed to be effective against multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa and other difficult-to-treat pathogens. The peptide-based mechanism offers a novel approach distinct from traditional antibiotics.

Approved indications

• Diabetic foot ulcers with Pseudomonas aeruginosa infection
• Multidrug-resistant gram-negative bacterial infections

Common side effects

• Local injection site reactions
• Pain at application site
• Erythema

Key clinical trials

• MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers (PHASE3)
• MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers (PHASE3)
• Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (PHASE3)
• Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MSI-78 CI brief — competitive landscape report
• MSI-78 updates RSS · CI watch RSS
• Abeona Therapeutics, Inc portfolio CI